Changes in Cervical Cytology Results and HPV Types among Persons Screened for Cervical Cancer, 2007 and 2015–2017

Details

• Alternative Title:
  J Low Genit Tract Dis
• Personal Author:
  Lewis, Rayleen M. ; Naleway, Allison L. ; Klein, Nicola P. ; Crane, Bradley ; Hsiao, Amber ; Aukes, Laurie ; Timbol, Julius ; Querec, Troy D. ; Steinau, Martin ; Weinmann, Sheila ; Unger, Elizabeth R. ; Markowitz, Lauri E.
  More +
• Description:
  Objectives: ; Since 2006, the U.S. human papillomavirus (HPV) vaccination program has led to decreases in HPV infections caused by high-risk vaccine-targeted HPV types (HPV16/18). We assessed differences in high-risk HPV prevalence by cervical cytology result among 20–24-year-old persons participating in routine cervical cancer screening in 2015–2017 compared to 2007. ; Methods: ; Residual routine cervical cancer screening specimens were collected from 20–24-year-old members of two integrated healthcare delivery systems as part of a cross-sectional study and were tested for 37 HPV types. Cytology results and vaccination status (≥1 dose) were extracted from medical records. Cytology categories were normal, atypical squamous cells of undefined significance (ASCUS), low-grade squamous intraepithelial lesions (SIL; LSIL), or high-grade SIL/atypical squamous cells cannot exclude high-grade SIL (HSIL/ASC-H). Prevalences of HPV categories (HPV16/18, HPV31/33/45/52/58, HPV35/39/51/56/59/66/68) were estimated by cytology result for 2007 and 2015–2017. ; Results: ; Specimens from 2007 (n=4046) were from unvaccinated participants; 4574 of 8442 (54.2%) specimens from 2015–2017 were from vaccinated participants. Overall, HPV16/18 positivity was lower in 2015–2017 compared to 2007 in all groups: HSIL/ASC-H, 16.0% vs 69.2%; LSIL, 5.4% vs 40.1%; ASCUS, 5.0% vs 25.6%; normal, 1.3% vs 8.1%. HPV31/33/45/52/58 prevalence was stable for all cytology groups; HPV35/39/51/56/59/66/68 prevalence increased among LSIL specimens (53.9% to 65.2%) but remained stable in other groups. ; Conclusions: ; Prevalence of vaccine-targeted high-risk HPV types 16/18 was dramatically lower in 2015–2017 than 2007 across all cytology result groups while prevalence of other high-risk HPV types was mainly stable, supporting vaccine impact with no evidence of type replacement.
• Subjects:
  • Adult
  • Cross-Sectional Studies
  • Early Detection of Cancer
  • Female
  • Human papillomavirus 16
  • Human papillomavirus 18
  • Humans
  • Uterine Cervical Neoplasms
  • Young Adult
• Keywords:
  • human papillomavirus
  • HPV vaccine
  • vaccination
  • cervical cancer screening
  • prevalence
  • cervical cytology
• Source:
  J Low Genit Tract Dis. 26(2):135-139
• Pubmed ID:
  35316258
• Pubmed Central ID:
  PMC8972086
• Document Type:
  Text
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Genre:
  Journal Article
• Volume:
  26
• Issue:
  2
• Download URL:
  https://stacks.cdc.gov/view/cdc/115871/cdc_115871_DS1.pdf
• File Type:
  [PDF - 446.24 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:e0af3932248fbfa59de9fefd9aad69d5708f391f0a02f320447585913a57194818036e1c61880cc9ff0e1a7deca0c920d44f22d22fc11c18c089f6d5b39eea75